Chemotherapy-induced Thrombocytopenia Clinical Trials

35 clinical trials for Chemotherapy-induced Thrombocytopenia across international registries, including 8 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gastrointestinal Solid Tumors — RECRUITING · PHASE2
• Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gynecologic, Breast, or Lung Solid Tumors — RECRUITING · PHASE2
• Romiplostim N01 for Chemotherapy-Induced Thrombocytopenia in Pediatric Cancer Patients — RECRUITING · PHASE2
• Single Arm Romiplostim to Prevent CIT — RECRUITING · PHASE1
• Home Monitoring of Complete Blood Count Performed by Patients - a Pilot Study on the Implementation Process in South Baltic Countries. — RECRUITING
• Romiplostim N01 for Chemotherapy-induced Thrombocytopenia — RECRUITING · PHASE2
• Herombopag for Chemotherapy-induced Thrombocytopenia — RECRUITING · PHASE2
• Eltrombopag for Chemotherapy-induced Thrombocytopenia — RECRUITING · PHASE2
• A Randomized, Multi-Center, Double-Blind, Phase III Study Evaluating the Efficacy and Safety of Hetrombopag Olamine Tablets vs Placebo in Patients with Chemotherapy-Induced Thrombocytopenia — TERMINATED · PHASE3
• Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer — ACTIVE_NOT_RECRUITING · PHASE3
• Avatrombopag vs. Placebo for CIT in GI Malignancies — ACTIVE_NOT_RECRUITING · PHASE2
• A Clinical Study on the Efficacy and Safety of Hetrombopag in the Treatment of Thrombocytopenia Induced by Gynecological Tumor Therapy — NOT_YET_RECRUITING · PHASE2
• Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer — COMPLETED · PHASE3
• A Clinical Trial Evaluating SCB-219M in in Chemotherapy-induced Thrombocytopenia (CIT) — ACTIVE_NOT_RECRUITING · PHASE1
• Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Subjects With Malignancy. — COMPLETED · PHASE3
• Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Solid Tumors. — ACTIVE_NOT_RECRUITING · PHASE3
• A Study of PN20 in Healthy Adult Volunteers — COMPLETED · PHASE1
• Avatrombopag for Chemotherapy-induced Thrombocytopenia — OTHER · PHASE2
• Evaluating the Efficacy and Safety of QL0911 in the Prevention of Chemotherapy- Induced Thrombocytopenia — COMPLETED · PHASE2
• Romiplostim in Chemotherapy-Induced Thrombocytopenia — OTHER · PHASE3
• The Efficacy and Safety of Hetrombopag as Secondary Prevention to Chemotherapy-induced Thrombocytopenia in Patients With Gynecologic Malignancies — OTHER · PHASE2
• Avatrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Active Non-Hematological Cancers — COMPLETED · PHASE3
• A Clinical Study of Hetrombopag Olamine Tablets in Adults Receiving 21-day Cycles of Chemotherapy for Solid Tumours, Who Are Delayed for at Least 1 Week From Their Scheduled Cycle Because of Chemotherapy-induced Thrombocytopenia — WITHDRAWN · PHASE3
• Hetrombopag in Secondary Prevention of XPO-1 Inhibitor-induced Thrombocytopenia in Lymphoma — OTHER · PHASE2
• Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia(CIT) in Patients With Acute Myeloid Leukemia — NOT_YET_RECRUITING · PHASE2
• Evaluating the Efficacy and Safety of QL0911 in Chemotherapy- Induced Thrombocytopenia — COMPLETED · PHASE2
• To Evaluate Thrombosis Risk in Chemotherapy Patients With Solid Tumors Who Receiving Thrombocytopenia Treatment — COMPLETED
• A Phase Ⅲa Study of Genetically Modified Recombinant Human Interleukin-11 — COMPLETED · PHASE3
• Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Lymphoma. — WITHDRAWN · PHASE3
• A Study of the Recombinant Human Interleukin-11 (I) (Baijieyi) for Prevention and Treatment of Chemotherapy-induced Thrombocytopenia in Patients With Malignant Tumor — OTHER
• Extended Platelet Parameters as a Means to Differentiate Immune Thrombocytopenia From Hypo-proliferative Thrombocytopenias. — COMPLETED
• A Study of the Safety and Efficacy of ONO-7746 in Adult Cancer Patients With Chemotherapy Induced Thrombocytopenia — TERMINATED · PHASE1
• Dose/ Schedule Finding Trial of Romiplostim for Chemotherapy-Induced Thrombocytopenia (CIT) in Non-Small Cell Lung Cancer (NSCLC) — COMPLETED · PHASE2
• Application of AS101 for the Treatment of Thrombocytopenia in Solid Tumor Patients — TERMINATED · PHASE2
• A Dose and Schedule Finding Trial With AMG 531 for Chemotherapy Induced Thrombocytopenia (CIT) in Adults With Lymphoma — COMPLETED · PHASE1

Refine this search